Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients

NCT00396045 is registered in ClinicalTrials.gov with University of Turin, Italy as lead sponsor.

NCT NCT00396045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00396045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open Label Study of Oral Melphalan, Prednisone, and CC-5013 (Revlimid) (MPR) as Induction Therapy in Elderly Newly Diagnosed Multiple Myeloma Patients
Lead sponsor
University of Turin, Italy
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2005
Completion date
January 31, 2008
Enrollment
54
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma